Medical Device Strategy Consulting and Pharma Market Access: Getting Regulated Products to Patients

Bringing a medical device or a pharmaceutical product to the U.S. market involves two very different regulatory pathways, but the underlying commercial challenge is strikingly similar: a product can be scientifically or clinically sound and still fail commercially if reimbursement, provider adoption, and market positioning aren’t planned early. Medical device strategy consulting and pharma market access services exist to solve exactly this problem, each within its own regulatory and payer landscape.

This article looks at what each discipline covers, where device and pharma commercialization challenges overlap, and what to consider when selecting a consulting partner in either space.

What Medical Device Strategy Consulting Covers

Medical device strategy consulting goes beyond regulatory submission support. While FDA classification (Class I, II, or III) and quality system compliance are foundational, strategic consulting also addresses reimbursement coding, provider adoption barriers, competitive positioning, and go-to-market sequencing — questions that determine whether a cleared or approved device actually gets used.

Regulatory Strategy as a Starting Point, Not the Whole Plan

Determining a device’s regulatory classification shapes the entire development timeline and cost structure, but classification alone doesn’t guarantee adoption. A Class II device with 510(k) clearance can still stall commercially if hospitals can’t find an appropriate reimbursement code or if the workflow change required for clinicians is too disruptive.

Reimbursement and Coding Complexity

Unlike pharmaceuticals, many medical devices don’t have a dedicated reimbursement pathway and instead rely on existing procedure codes, which can undervalue a novel device’s benefit or require a lengthy new-code application process. Strategic consultants help manufacturers map this landscape early, often well before FDA submission, so commercialization isn’t an afterthought.

Provider Adoption and Workflow Fit

Even well-reimbursed devices fail if they require significant workflow disruption without a clear enough benefit to justify the change. Strategy consulting increasingly includes human factors and workflow analysis to identify adoption friction before launch, not after.

What Pharma Market Access Services Cover

Pharma market access services focus on securing and maintaining favorable payer coverage, formulary placement, and pricing for a drug once it moves toward or through FDA approval. This includes payer value proposition development, pricing and contracting strategy, and engagement with pharmacy and therapeutics (P&T) committees that ultimately decide formulary placement.

Why Market Access Planning Starts Early

Payer and formulary decisions are typically made within the first 90 days after FDA approval, but the groundwork — the clinical evidence package, health economic modeling, and payer engagement — needs to begin well before approval. Companies that wait until post-approval to build their market access case often face avoidable delays or unfavorable formulary tiers.

Formulary Tiers and Utilization Management

Drugs placed on preferred formulary tiers see significantly better uptake than those requiring prior authorization or facing step-therapy requirements. Market access consultants work to build the clinical and economic case needed to secure the most favorable tier possible.

Where Device and Pharma Commercialization Strategy Overlap

Both disciplines share a core insight: regulatory approval is a milestone, not the finish line. Both require early, evidence-based engagement with payers or reimbursement bodies, both depend on understanding how the end user (clinician or patient) will actually behave once the product is available, and both benefit from involving commercial strategy input during development rather than only after approval or clearance. It’s why a growing number of life sciences consulting firms serve both device and pharma clients under a shared commercialization practice.

Selection Criteria for a Consulting Partner

• Confirm direct experience with your product category’s specific regulatory pathway (510(k), PMA, De Novo for devices; NDA/BLA for drugs)
• Ask for examples of how they’ve influenced payer or formulary outcomes, not just regulatory submissions
• Evaluate whether their team includes former payer, reimbursement, or health economics specialists
• Check how early in development they typically engage — the best market access and device strategy work starts well before submission
• Understand their approach to evidence generation, since payer decisions increasingly hinge on real-world data, not just clinical trial results

Common Challenges and Best Practices

The most common mistake in both device and pharma commercialization is treating reimbursement strategy as a post-approval task. Engaging market access or device strategy expertise during clinical development — not after — consistently produces better coverage outcomes and faster time to meaningful adoption.

FAQs / Q&A

Q1. When should a medical device company start commercialization strategy work? Ideally during early development, before the regulatory pathway is finalized, since classification and reimbursement strategy decisions influence each other.

Q2. What’s the difference between FDA clearance and market access for a medical device? FDA clearance or approval confirms a device is safe and effective enough to sell; market access refers to the separate challenge of securing reimbursement and driving provider adoption once it’s cleared.

Q3. How do payers decide which drugs get preferred formulary placement? Pharmacy and therapeutics committees evaluate clinical evidence, cost-effectiveness, and comparative value against existing treatments, typically within the first few months after FDA approval.

Q4. Can a small MedTech startup afford strategy consulting, or is it only for larger companies? Early-stage strategic input is often more valuable for smaller companies, since a misjudged regulatory or reimbursement pathway can be far more costly to correct later with limited runway.

Q5. Do pharma market access services differ for specialty drugs versus common medications? Yes significantly — specialty and high-cost therapies typically face more intensive utilization management and prior authorization requirements, requiring a more detailed market access strategy than common lower-cost medications.

Q6. Is medical device reimbursement strategy handled differently than drug reimbursement? Yes. Devices often rely on existing procedure codes rather than a dedicated new-product reimbursement pathway, which creates a different, sometimes more fragmented, strategic challenge than pharmaceutical formulary placement.